HEOR

1. Health Economics Modeling

• Cost-effectiveness Analysis (CEA): Assessing the value of an intervention by comparing its costs and outcomes (e.g., QALYs) against other options.
• Budget Impact Modeling (BIA): Estimating the financial impact of adopting a new treatment within a specific healthcare budget over time.
• Cost-Utility Analysis (CUA): A form of CEA that uses utilities (like QALYs) to evaluate interventions.
• Markov Models: A mathematical technique representing long-term outcomes, especially for chronic disease management.

2. Outcomes Research

• Clinical Outcomes Assessment: Measuring effectiveness on outcomes such as survival rate or symptom reduction.
• Patient-Reported Outcomes (PROs): Data on patient health status, quality of life, and satisfaction.
• Real-World Evidence (RWE): Using registries, EHR, and claims data to understand real-world performance.

3. Cost Analysis

• Direct & Indirect Costs: Evaluation of treatment, hospital stays, productivity loss, and caregiving costs.
• Resource Utilization: Analysis of healthcare usage — hospital visits, medication, physician consultations.

4. Health Technology Assessment (HTA)

• Evaluating clinical and economic value of new technologies, drugs, or devices.
• Includes scientific evidence review, economic analysis & system impact assessment.

5. Reimbursement Strategy & Pricing

• Value Dossier Preparation: Clinical, economic & outcomes data for payer submissions.
• Pricing Strategy: Market access, competitive pricing & value-based pricing models.

6. Market Access Services

• Strategies to overcome reimbursement barriers & negotiate with payers.
• Payer engagement to demonstrate cost-effectiveness & value.

7. Comparative Effectiveness Research (CER)

• Direct comparison of intervention effectiveness in real-world applications.

8. Regulatory Support

• Support for submissions to regulatory bodies.
• Post-market surveillance for real-world performance.

9. Patient-Reported Outcomes (PRO) Research

• Collecting patient-centered quality-of-life and satisfaction data.

Common Stakeholders & Beneficiaries

• Pharmaceutical companies • Biotech & device companies • Healthcare providers
• Health insurance payers • Regulatory agencies • Governments & policymakers

Why HEOR Is Important

• Supports value-based healthcare
• Informs reimbursement decisions
• Helps set pricing strategies
• Guides healthcare policy & investment decisions